公开(公告)号：US20240010738A1

公开(公告)日：2024-01-11

申请号：US18464407

申请日：2023-09-11

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Shinya Ishii ,  Atsuhiko Maeda ,  Mika Sakurai ,  Tetsuo Kojima ,  Tatsuhiko Tachibana ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Yoshinobu Higuchi

IPC分类号： C07K16/28 ,  C07K16/46

CPC分类号： C07K16/2866 ,  C07K16/461 ,  A61K2039/505

摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.
The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

公开(公告)号：US20180079817A1

公开(公告)日：2018-03-22

申请号：US15563743

申请日：2016-04-13

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： Akihisa Kaneko ,  Yuki Iwayanagi ,  Hidetomo Kitamura ,  Yoshinobu Higuchi ,  Hiroaki Matsushita ,  Ryosuke Mihara ,  Yumi Yamamoto ,  Tomohisa Saito ,  Keiko Hirokawa

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06

摘要： In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

公开(公告)号：US20240301075A1

公开(公告)日：2024-09-12

申请号：US18651896

申请日：2024-05-01

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Shinya Ishii ,  Atsuhiko Maeda ,  Mika Sakurai ,  Tetsuo Kojima ,  Tatsuhiko Tachibana ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Yoshinobu Higuchi

IPC分类号： C07K16/28 ,  A61K39/00 ,  C07K16/46

CPC分类号： C07K16/2866 ,  C07K16/461 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.
The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

公开(公告)号：US10662245B2

公开(公告)日：2020-05-26

申请号：US14520423

申请日：2014-10-22

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Shinya Ishii ,  Atsuhiko Maeda ,  Mika Sakurai ,  Tetsuo Kojima ,  Tatsuhiko Tachibana ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Yoshinobu Higuchi

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/46 ,  A61K39/00

摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

公开(公告)号：US11773173B2

公开(公告)日：2023-10-03

申请号：US16713271

申请日：2019-12-13

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： Akihisa Kaneko ,  Yuki Iwayanagi ,  Hidetomo Kitamura ,  Yoshinobu Higuchi ,  Hiroaki Matsushita ,  Ryosuke Mihara ,  Yumi Yamamoto ,  Tomohisa Saito ,  Keiko Hirokawa

IPC分类号： A61K39/395 ,  A61K39/00 ,  C07K16/28 ,  C07K16/24 ,  A61K45/00 ,  A61K45/06

CPC分类号： C07K16/2866 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/00 ,  A61K45/06 ,  C07K16/24 ,  C07K16/28 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/76 ,  C07K2317/94

摘要： In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

公开(公告)号：US20230159648A1

公开(公告)日：2023-05-25

申请号：US18096066

申请日：2023-01-12

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Shinya Ishii ,  Atsuhiko Maeda ,  Mika Sakurai ,  Tetsuo Kojima ,  Tatsuhiko Tachibana ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Yoshinobu Higuchi

IPC分类号： C07K16/28 ,  C07K16/46

CPC分类号： C07K16/2866 ,  C07K16/461 ,  A61K2039/505

摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.
The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

公开(公告)号：US20200231688A1

公开(公告)日：2020-07-23

申请号：US16838415

申请日：2020-04-02

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Shinya Ishii ,  Atsuhiko Maeda ,  Mika Sakurai ,  Tetsuo Kojima ,  Tatsuhiko Tachibana ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Yoshinobu Higuchi

IPC分类号： C07K16/28 ,  C07K16/46

摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

公开(公告)号：US20240018249A1

公开(公告)日：2024-01-18

申请号：US18366770

申请日：2023-08-08

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Akihisa Kaneko ,  Yuki lwayanagi ,  Hidetomo Kitamura ,  Yoshinobu Higuchi ,  Hiroaki Matsushita ,  Ryosuke Mihara ,  Yumi Yamamoto ,  Tomohisa Saito ,  Keiko Hirokawa

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/00 ,  A61K45/06 ,  C07K16/24

CPC分类号： C07K16/2866 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/00 ,  A61K45/06 ,  C07K16/24 ,  C07K16/28 ,  C07K2317/94 ,  A61K2039/505

摘要： In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

公开(公告)号：US20220306755A1

公开(公告)日：2022-09-29

申请号：US17829641

申请日：2022-06-01

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Shinya Ishii ,  Atsuhiko Maeda ,  Mika Sakurai ,  Tetsuo Kojima ,  Tatsuhiko Tachibana ,  Hirotake Shiraiwa ,  Hiroyuki Tsunoda ,  Yoshinobu Higuchi

IPC分类号： C07K16/28 ,  C07K16/46

摘要： The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions.
The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

公开(公告)号：US10544227B2

公开(公告)日：2020-01-28

申请号：US15563743

申请日：2016-04-13

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： Akihisa Kaneko ,  Yuki Iwayanagi ,  Hidetomo Kitamura ,  Yoshinobu Higuchi ,  Hiroaki Matsushita ,  Ryosuke Mihara ,  Yumi Yamamoto ,  Tomohisa Saito ,  Keiko Hirokawa

IPC分类号： A61K39/395 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28

摘要： In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.